We're off to the races!

Sangamo and Pfizer Announce Updated Results of Investigational Hemophilia A Gene Therapy

The following is an excerpt from a press release from Sangamo. Read the press release in its entirety here. Sangamo Therapeutics Inc., a genomic medicine company, and Pfizer Inc. announced updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A.The data showed that SB-525 was generally well-tolerated and […]

Bayer to present new data at Congress of International Society on Thrombosis and Haemostasis

The following is an excerpt of a press release from Bayer. Read the press release in its entirety here. Bayer will present new data highlighting clinical outcomes from its hemophilia A portfolio, which include long-term data from the PROTECT VIII investigational study evaluating use of Jivi® antihemophilic factor (recombinant) PEGylated-aucl. These data will be presented […]

BioMarin Announces Update to Hemophilia A Clinical Development Program

The following is an excerpt from a press release from BioMarin. Read the press release in its entirety here. BioMarin Pharmaceutical Inc. announced its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A achieved pre-specified clinical criteria for regulatory review in the U.S. and Europe. As of May 28, 2019, eight patients in […]

uniQure Presents Updated Clinical Data on Gene Therapy for Hemophilia B

The following is an excerpt from a press release from uniQure. Read the full press release here. uniQure announced updated clinical data in patients treated in the company’s ongoing Phase IIb study of AMT-061, an investigational AAV5-based gene therapy containing a patent-protected FIX-Padua variant, for the treatment of patients with severe and moderately severe hemophilia B. […]

uniQure Announces New Preclinical Data in Hemophilia A and Fabry Disease

The following is an excerpt from a press release from uniQure. Read the press release in its entirety here. uniQure N.V., a gene therapy company, presented new preclinical data on its gene therapy candidates for the treatment of hemophilia A and for the treatment of Fabry disease during back-to-back oral presentations at the 22nd American Society […]

Recall Notice: Fentanyl Transdermal Pain Patches Recalled Due to Product Mislabeling

The following is from the FDA MedWatch. Read the recall notice in its entirety here. Alvogen Inc. is voluntarily recalling two lots of Fentanyl Transdermal System 12 mcg/h transdermal patches to the consumer level. A small number of cartons labeled 12 mcg/h Fentanyl Transdermal System patches contained 50 mcg/h patches. The 50 mcg/h patches that […]

Sanofi Genzyme Launches Innovative and Educational Audio Adventure Series for People Treated with ALPROLIX®

The following is a press release from Sanofi Genzyme. Find the full press release here. Sanofi Genzyme, the specialty care business unit of Sanofi, announced the launch of a first-of-its-kind audio adventure series designed to provide an engaging and educational infusion experience for ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] patients and their caregivers.Part […]

Spark Therapeutics Enters into Merger Agreement with Roche

The following is an excerpt from a press release from Spark Therapeutics. Read the press release in its entirety here. Spark Therapeutics , a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it has entered into a definitive merger agreement for Roche to fully acquire Spark […]

en_USEnglish